Brendan P. Major

Brendan P. Major

Auto-generated profile, based on publicly available information

Brendan P. Major

Department of Neuroscience, School of Translational Medicine, Monash University, Victoria, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
LFLara Fernandez
Lara Fernandez
BMBrendan P. Major
Brendan P. Major
WTWei-Peng Teo
Wei-Peng Teo
LBLinda K. Byrne
Linda K. Byrne
PEPeter Enticott
Peter Enticott

1 March 2014 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
MAMatti D. Allen
Matti D. Allen
BMBrendan Major
Brendan Major
KKKurt Kimpinski
Kurt Kimpinski
TDTimothy J. Doherty
Timothy J. Doherty
CRCharles L. Rice
Charles L. Rice
The objective of the study was to assess the effects of diabetic polyneuropathy (DPN) on muscle contractile properties in humans, and how these changes are related to alterations in muscle morphology and denervation. Patients with DPN ( n = 12) were compared with age- and sex-matched controls ( n = 12). Evoked and voluntary contractile properties, including stimulated twitch responses and maximal voluntary contractions, of the dorsiflexor muscles were assessed using an isometric ankle dynamometer. Motor unit number estimates (MUNE) of the tibialis anterior (TA) were performed via quantitative electromyography and decomposition-enhanced spike-triggered averaging. Peak tibialis anterior (TA) cross-sectional area (CSA; cm2), and relative proportion of contractile to noncontractile tissue (%) was determined from magnetic resonance images. Patients with DPN demonstrated decreased strength (−35%) and slower (−45%) dorsiflexion contractile properties for both evoked and voluntary contractions ( P < 0.05). These findings were not accounted for by differences in voluntary activation ( P > 0.05) or antagonist coactivation ( P > 0.05). Additionally, patients with DPN were weaker when strength was normalized to TA total CSA (−30%; P < 0.05) or contractile tissue CSA (−26%; P < 0.05). In the DPN patient group, TA MUNEs were negatively related to both % noncontractile tissue ( P < 0.05; r = 0.72) and twitch half-relaxation time ( P < 0.05; r = 0.60), whereas no relationships were found between these variables in controls ( P > 0.05). We conclude that patients with DPN demonstrated reduced strength and muscle quality as well as contractile slowing. This process may contribute to muscle power loss and functional impairments reported in patients with DPN, beyond the loss of strength commonly observed.

6 January 2020 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
LFLara Fernandez
Lara Fernandez
NRNigel C. Rogasch
Nigel C. Rogasch
MDMichael Do
Michael Do
GCGillian Clark
Gillian Clark
BMBrendan P. Major
Brendan P. Major
PEPeter Enticott
Peter Enticott

14 November 2023 in Neurology
Verified
Journal Article
Open access
PDF file
JRJonathan Reyes
Jonathan Reyes
GSGershon Spitz
Gershon Spitz
BMBrendan P. Major
Brendan P. Major
WOWilliam T. O'Brien
William T. O'Brien
LGLauren P. Giesler
Lauren P. Giesler
SMStuart J. McDonald
Stuart J. McDonald
Background and Objectives Blood biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) have recently been Food and Drug Administration approved as predictors of intracranial lesions on CT after mild traumatic brain injury (mTBI). However, most cases with mTBI are CT negative, and no biomarkers are approved to assist diagnosis in these individuals. In this study, we aimed to determine the optimal combination of blood biomarkers to assist mTBI diagnosis in otherwise healthy adults younger than 50 years presenting to an emergency department within 6 hours of injury. To further understand the utility of biomarkers, we assessed how biological sex, presence or absence of loss of consciousness and/or post-traumatic amnesia (LOC/PTA), and delayed presentation affected classification performance. Methods Blood samples, symptom questionnaires, and cognitive tests were prospectively conducted for participants with mTBI recruited from The Alfred Hospital Level 1 Emergency & Trauma Center and uninjured controls. Follow-up testing was conducted at 7 days. Simoa quantified plasma GFAP, UCH-L1, tau, neurofilament light chain (NfL), interleukin (IL)–6, and IL-1β. Area under the receiver operating characteristic (AUC) analysis assessed classification accuracy for diagnosed mTBI, and logistic regression models identified optimal biomarker combinations. Results Plasma IL-6 (AUC 0.91, 95% CI 0.86–0.96), GFAP (AUC 0.85, 95% CI 0.78–0.93), and UCH-L1 (AUC 0.79, 95% CI 0.70–0.88) best differentiated mTBI (n = 74) from controls (n = 44) acutely (<6 hours), with NfL (AUC 0.81, 95% CI 0.72–0.90) the only marker to have such utility subacutely (7 days). Biomarker performance was similar between sexes and for participants with and without LOC/PTA, with the exception at 7 days, where GFAP and IL-6 retained some utility in female participants (GFAP: AUC 0.71, 95% CI 0.55–0.88; IL-6: AUC 0.71, 95% CI 0.55–0.87) and in those with LOC/PTA (GFAP: AUC 0.73, 95% CI 0.59–0.86; IL-6: AUC 0.71, 95% CI 0.57–0.84). Acute IL-6 (R2 = 0.50, 95% CI 0.34–0.64) outperformed GFAP and UCH-L1 combined (R2 = 0.35, 95% CI 0.17–0.50), with the best acute model featuring GFAP and IL-6 (R2 = 0.54, 95% CI 0.34–0.68). Discussion These findings indicate that adding IL-6 to a panel of brain-specific proteins such as GFAP and UCH-L1 might assist in the acute diagnosis of mTBI in adults younger than 50 years. Multiple markers had high classification accuracy in participants without LOC/PTA. When compared with the best-performing acute markers, subacute measures of plasma NfL resulted in minimal reduction in classification accuracy. Future studies will investigate the optimal time frame over which plasma IL-6 might assist diagnostic decisions and how extracranial trauma affects utility.

5 May 2018 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
LFLara Fernandez
Lara Fernandez
BMBrendan P. Major
Brendan P. Major
WTWei-Peng Teo
Wei-Peng Teo
LBLinda K. Byrne
Linda K. Byrne
PEPeter Enticott
Peter Enticott

6 September 2017 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
CLChristopher Latella
Christopher Latella
WTWei-Peng Teo
Wei-Peng Teo
DHDale Harris
Dale Harris
BMBrendan Major
Brendan Major
DVDan VanderWesthuizen
Dan VanderWesthuizen
AHAshlee M. Hendy
Ashlee M. Hendy